A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent
skin disorder. The purpose of this study is to compare the safety and efficacy of multiple
concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.